E01V0010 Human Vascular Endothelial Growth Factor ELISA kit
The Human Vascular Endothelial Growth Factor ELISA kit can be used to identify samples from the human species. Vascular Endothelial Growth Factor can also be called VEGF, Vascuoar endothelial growth factor A, VEGF A, vascular endothelial growth factor A isoform 2 precursor, Vegf, VEGFA, MVCD1, VEGF, Vascular endothelial growth factor A, VEGF-A, Vascular permeability factor, VPF, VEGF A Precursor.
Product Information | |
Cat. No. | E01V0010 |
Product Name | Human Vascular Endothelial Growth Factor ELISA kit |
Species | Human |
Product Size | 48 Tests / 96 Tests |
Concentration | 50-1000 pg/ml |
Sensitivity | 1.0 pg/ml |
Principal | Competitive ELISA |
Sample Volume | 100 ul |
Sample Type | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate |
Assay Time | 90 minutes |
Platform | Microplate Reader |
Conjugate | HRP |
Detection Method | Colorimetric |
Storage | 2-8°C |
Kit Components | ||
MATERIALS | SPECIFICATION | QUANTITY |
MICROTITER PLATE | 96 wells | stripwell |
ENZYME CONJUGATE | 6.0 mL | 1 vial |
STANDARD A (0.5mL) | 0 pg/mL | 1 vial |
STANDARD B (0.5mL) | 50 pg/mL | 1 vial |
STANDARD C (0.5mL) | 100 pg/mL | 1 vial |
STANDARD D (0.5mL) | 250 pg/mL | 1 vial |
STANDARD E (0.5mL) | 500 pg/mL | 1 vial |
STANDARD F (0.5mL) | 1000 pg/mL | 1 vial |
SUBSTRATE A | 6 mL | 1 vial |
SUBSTRATE B | 6 mL | 1 vial |
STOP SOLUTION | 6 mL | 1 vial |
WASH SOLUTION (100 x) | 10 mL | 1 vial |
BALANCE SOLUTION | 3 mL | 1 vial |
Principle of the Assay |
VEGF ELISA kit uses an anti-VEGF antibody and an VEGF-HRP conjugate in a competitive enzyme immunoassay method. VEGF-HRP conjugate is incubated with the assay sample and buffer in a pre-coated plate for one hour. The wells are decanted and washed five times when the incubation period is over. The HRP enzyme substrate is then incubated in the wells. The result of the enzyme-substrate reaction is a complex that is blue in hue. The process is finally stopped by adding a stop solution, causing the solution to turn yellow. In a microplate reader, the color intensity is measured spectrophotometrically at 450 nm. Due to competition for the anti-VEGF antibody binding site between VEGF from samples and VEGF-HRP conjugate, the intensity of the color is inversely proportional to the concentration of VEGF. Since the number of sites is limited, as more sites are occupied by VEGF from the sample, fewer sites are left to bind VEGF-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The VEGF concentration in each sample is interpolated from this standard curve. |
Coefficient of Variance | Intra Variation% ＜10% | |
Inter Variation% ＜12% | ||
Recovery | 95-102% | |
Linearity | Diluent Ratio | Range % |
1:2 | 93-105 | |
1:4 | 88-106 | |
1:8 | 86-108 | |
Specificity/Cross-reactivity | No significant cross-reactivity or interference between VEGF and analogues was observed. | |
E01V0010 has been referenced in the below publications：
Emodin-Loaded Magnesium Silicate Hollow Nanocarriers for Anti-Angiogenesis Treatment through Inhibiting VEGF.
The relationship between circulating tissue transglutaminase, soluble fms-like tyrosine kinase-1, soluble endoglin and vascular endothelial growth factor in pre-eclampsia.
Comparison of the Effectiveness of High-Intensity Interval Training in Hypoxia and Normoxia in Healthy Male Volunteers:A Pilot Study.
The role and mechanism of asymmetric dimethylarginine in fetal growth restriction via interference with endothelial function and angiogenesis.
The Effect of High-Intensity Interval Exercise on Short-Term Glycaemic Control, Serum Level of Key Mediator in Hypoxia and Pro-Inflammatory Cytokines in Patients with Type 1 Diabetes—An Exploratory Case Study.
Related Bluegene Biotech Products
BlueGene Biotech News
